As Pfizer considered changing its business mix, the $67.8 billion pharmaceutical maker wanted to get a better handle on the best capital structure for the company. So treasury built a dynamic model that takes into account Pfizer's balance sheet and cash flow forecasts to determine an appropriate capital structure.
Amit Singh, Pfizer's senior director of capital markets, says standard models for a company's capital structure focus mostly on tax benefits related to leverage and distress costs. The traditional analysis usually ends up suggesting the amount of leverage equal to a Triple-B credit rating is appropriate, he says.
Pfizer wanted to take into account many other factors, including cash on the balance sheet and its possible uses, the location of that cash and any challenges in repatriating it, changes in global taxes and payouts to shareholders.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
- Exclusive discounts on ALM and Treasury & Risk events.
- Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.
*May exclude premium content
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
